Home Industry Nanotechnology Can Microemulsion Nanotechnolo...
CIO Bulletin, 17 November, 2026
Author:
Sambhrant Das
University of Alberta pharmacy researchers develop FoamaDerm, nanotechnology microemulsion foam that delivers faster topical pain relief for chronic conditions like arthritis at lower drug concentrations while simplifying pharmacy compounding.
Pharmacy researchers at the University of Alberta have developed a nanotechnology-based foaming solution that provides much faster and more effective topical pain relief than conventional creams and ointments. The product, called Foamaderm and developed at the University's Drug Development and Innovation Centre under the direction of pharmacy professor Dr. Raimar Löbenberg, works at a two per cent concentration of active drug (diclofenac). This is in contrast to the standard compounded diclofenac creams, which typically require 5- 10% active drug.
Lab studies have shown that conventional topical formulations have a real problem in terms of getting through the outer barrier of the skin. Researchers now improve the release of active anti-inflammatory substances via microemulsion foam and, thereby, deliver medication faster than ever:
Dispenses via a propellant free pump which produces a fast absorbing foam with absolutely no greasy residue on skin or clothing.
Eliminates the need for chemical solvents, mechanical grinding or specialist compounding equipment in the retail pharmacy.
Enables the pharmacist to simply dissolve the active diclofenac directly into the liquid base in a matter of minutes.
Dr Löbenberg made it very clear that improving clinical outcomes is often about re-engineering the way established drugs get into tissue rather than just coming up with new molecules.
Explaining his team's specialized approach to translational pharmaceutical science, Löbenberg stated, "We look at the different areas of the body where you want to target a drug and figure out the mechanism to get it there. We really are the drug delivery people."
His spin-off, RS Therapeutics Inc., is currently the supplier of the base in Canadian pharmacies and is now moving into a new lab in North Carolina.
Following very strong uptake by Canadian compounding pharmacies, the research group is now looking at the microemulsion foam as a potential carrier for a range of other drugs in addition to the NSAIDS. Ongoing translational initiatives at the Edmonton research center include:
Evaluating FoamaDerm as a transdermal delivery system for other targeted therapeutic agents.
Developing inhalable nanoparticle powders designed to deliver anti-cancer drugs directly into the lung.
Creating dissolvable edible strips and lymphatic drug delivery systems that target the drug precisely.
Thus, the progress of transdermal drug delivery brings about both effective control over chronic inflammation and the reduced occurrence of gastrointestinal side effects from oral painkillers. According to CIO Bulletin, the application of formulation science is of great value for pharmacy compounding because targeted pharmaceutical nanotechnology improves patient comfort and makes the process of preparing medications that much easier.
News Source: University of Alberta, https://www.ualberta.ca/en/index.html
Everything you need to know about this news
FoamaDerm is a nanotechnology-based microemulsion foam developed at the University of Alberta's Drug Development and Innovation Centre (DDIC) under the direction of Dr. Raimar Löbenberg to improve the delivery of topical medications.
Standard compounded creams generally require 5-10% diclofenac. FoamaDerm has a double release rate at just 2% strength and absorbs very cleanly with no skin or clothing residue.
Pharmacists can simply dissolve the active diclofenac directly into the water and coconut oil liquid base in a matter of minutes without the need for any chemical solvents, grinding equipment, or specialist compounding machinery.
Topical non-steroidal anti-inflammatories act directly on the joint and muscle pain via the skin and so reduce the risk of the more serious gastric side effects (upset, ulceration) associated with oral NSAIDs.
Via its spin-off company, RS Therapeutics Inc., FoamaDerm is currently available to compounding pharmacies throughout Canada, and there is a new lab in North Carolina to support the US market.








Comments